Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-05-03
2005-05-03
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S614000, C514S615000, C514S558000
Reexamination Certificate
active
06887863
ABSTRACT:
Compounds having the formulaare methionine aminopeptidase type 2 (MetAP2) inhibitors and are useful for inhibiting angiogenesis. Also disclosed are MetAP2-inhibiting compositions and methods of inhibiting angiogenesis in a mammal.
REFERENCES:
patent: 5977408 (1999-11-01), Levin et al.
patent: 9831710 (2000-01-01), None
patent: 266950 (1988-05-01), None
patent: 9942436 (1999-08-01), None
patent: 9957098 (1999-11-01), None
Castro-Pichel, et al., “Synthesis & antiviral & cystatic activities,” Nucleos. & Nucleit. 9(7):985-1000 (1990).
Griffith, E.C., “Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin,” Chemistry and Biology 4(6):461-471 (1997).
Sin, Ny; “The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2,” Proc. National Academy of Science USA 94:6099-6103 (1997).
Ba-Maung Nwe
Craig Richard A.
Kawai Megumi
Lynch Linda M.
Patel Jyoti R.
Abbott Laboratories
Donner B. Gregory
Patel Sudhaker B.
Raymond Richard L.
LandOfFree
Hydrazide and alkoxyamide angiogenesis inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydrazide and alkoxyamide angiogenesis inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydrazide and alkoxyamide angiogenesis inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3404442